Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

被引：8

作者：

Ciccarese, Chiara ^{[1
]}

Montironi, Rodolfo ^{[2
]}

Fiorentino, Michelangelo ^{[3
]}

Martignoni, Guido ^{[4
,5
]}

Brunelli, Matteo ^{[4
]}

Iacovelli, Roberto ^{[1
]}

Lopez-Beltran, Antonio ^{[6
,7
]}

Cheng, Liang ^{[8
]}

Scarpelli, Marina ^{[2
]}

Moch, Holger ^{[9
]}

Tortora, Giampaolo ^{[1
]}

Massari, Francesco ^{[10
]}

机构：

[1] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Verona, Italy

[2] Polytech Univ Marche Reg, Sch Med, AOU Osped Riuniti, Sect Pathol Anat, Ancona, Italy

[3] St Orsola Marcello Malpighi Hosp, Addarii Inst Oncol, Pathol Serv, Bologna, Italy

[4] Univ Verona, AOUI, Dept Pathol & Diagnost, Verona, Italy

[5] Pederzoli Hosp, Anat Pathol, Verona, Italy

[6] Univ Cordoba, Med Sch, Dept Surg & Pathol, Cordoba, Spain

[7] Champalimaud Clin Ctr, Lisbon, Portugal

[8] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[9] Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, Zurich, Switzerland

[10] St Orsola Marcello Malpighi Hosp, Div Oncol, Bologna, Italy

来源：

CURRENT DRUG METABOLISM | 2017年 / 18卷 / 08期

关键词：

Prostate cancer; mCRPC; circulating tumor cells; CTCs; biomarker; malignancy; INCREASED SURVIVAL; PERIPHERAL-BLOOD; ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PREDNISONE; AMPLIFICATION; COUNTS; MARKER;

D O I：

10.2174/1389200218666170518163549

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-time biomarkers of prostate cancer. Conclusion: This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.

引用

页码：692 / 699

页数：8

共 50 条

[1] Circulating tumor cells and their role in prostate cancer
Maas, Moritz
Hegemann, Miriam
Rausch, Steffen
Bedke, Jens
Stenzl, Arnulf
Todenhoefer, Tilman
ASIAN JOURNAL OF ANDROLOGY, 2019, 21 (01): : 24 - 31
[2] Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
de Kruijff, Ingeborg E.
Sieuwerts, Anieta M.
Onstenk, Wendy
Kraan, Jaco
Smid, Marcel
Van, Mai N.
van der Vlugt-Daane, Michelle
Oomen-de Hoop, Esther
Mathijssen, Ron H. J.
Lolkema, Martijn P.
de Wit, Ronald
Hamberg, Paul
Meulenbeld, Hielke J.
Beeker, Aart
Creemers, Geert-Jan
Martens, John W. M.
Sleijfer, Stefan
CANCERS, 2019, 11 (08)
[3] A Systematic Review of Circulating Tumor Cells Clinical Application in Prostate Cancer Diagnosis
Enikeev, Dmitry
Morozov, Andrey
Babaevskaya, Diana
Bazarkin, Andrey
Malavaud, Bernard
CANCERS, 2022, 14 (15)
[4] Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
Lorente, David
Olmos, David
Mateo, Joaquin
Bianchini, Diletta
Seed, George
Fleisher, Martin
Danila, Daniel C.
Flohr, Penny
Crespo, Mateus
Figueiredo, Ines
Miranda, Susana
Baeten, Kurt
Molina, Arturo
Kheoh, Thian
McCormack, Robert
Terstappen, Leon W. M. M.
Scher, Howard I.
de Bono, Johann S.
EUROPEAN UROLOGY, 2016, 70 (06) : 985 - 992
[5] The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer
Onstenk, Wendy
de Kiaver, Willemijn
de Wit, Ronald
Lolkema, Martijn
Foekens, John
Sleijfer, Stefan
CANCER TREATMENT REVIEWS, 2016, 46 : 42 - 50
[6] Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy
Thalgott, M.
Heck, M. M.
Eiber, M.
Souvatzoglou, M.
Hatzichristodoulou, G.
Kehl, V.
Krause, B. J.
Rack, B.
Retz, M.
Gschwend, J. E.
Andergassen, U.
Nawroth, R.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (08) : 1457 - 1464
[7] Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer
Aragon-Ching, Jeanny B.
Siegel, Robert S.
Frazier, Harold, II
Andrawis, Ramez
Hendricks, Frederick
Phillips, Michael
Jarrett, Thomas
Guebre-Xabiher, Hiwot
Patierno, Steven
Simmens, Samuel J.
CLINICAL GENITOURINARY CANCER, 2015, 13 (05) : E341 - E345
[8] Can Biomarker Assessment on Circulating Tumor Cells Help Direct Therapy in Metastatic Breast Cancer?
Turner, Natalie
Pestrin, Marta
Galardi, Francesca
De Luca, Francesca
Malorni, Luca
Di Leo, Angelo
CANCERS, 2014, 6 (02) : 684 - 707
[9] In vivo isolation of circulating tumor cells in patients with different stages of prostate cancer
Theil, Gerit
Boehm, Catrin
Fischer, Kersten
Bialek, Joanna
Hoda, Raschid
Weber, Ekkehard
Schonburg, Sandra
Kawan, Felix
Fornara, Paolo
ONCOLOGY LETTERS, 2021, 21 (05)
[10] Circulating Tumor Cells as a Biomarker Predictive of Sensitivity to Docetaxel Chemotherapy in Patients with Castration-resistant Prostate Cancer
Okegawa, Takatsugu
Itaya, Naoshi
Hara, Hidehiko
Tambo, Mitsuhiro
Nutahara, Kikuo
ANTICANCER RESEARCH, 2014, 34 (11) : 6705 - 6710

← 1 2 3 4 5 →